Summary:
- The FDA's priority review of Regeneron's Eylea HD for macular edema could be a significant catalyst, with a decision expected by August 19, 2025.
- Analysts forecast a potential 65.75% upside with an average price target of $909.08.
- Regeneron holds an "Outperform" consensus rating, signaling strong investment potential.
FDA Review of Eylea HD: A Potential Breakthrough for Regeneron
Regeneron Pharmaceuticals (REGN, Financial) has announced that the U.S. Food and Drug Administration (FDA) will review a supplemental biologics license application for Eylea HD. This drug is aimed at treating macular edema following retinal vein occlusion, with plans for expanded dosing schedules. The FDA's decision, facilitated by a Priority Review voucher, is anticipated by August 19, 2025. This development could mark a significant milestone for Regeneron, given the potential market impact of Eylea HD.
Wall Street's Perspective: Price Targets and Analyst Ratings
Wall Street analysts have projected a promising future for Regeneron Pharmaceuticals Inc (REGN, Financial), with 25 analysts setting an average one-year price target of $909.08. With a range from a high estimate of $1,152.00 to a low of $575.00, the average target indicates a potential upside of 65.75% from the current price of $548.48. For more detailed estimates, visit the Regeneron Pharmaceuticals Inc (REGN) Forecast page.
Brokerage Recommendations: Strong Support for Regeneron
According to consensus from 28 brokerage firms, Regeneron Pharmaceuticals Inc (REGN, Financial) holds an "Outperform" average recommendation, with a score of 2.0 on a scale where 1 represents a Strong Buy and 5 denotes a Sell. This consensus underscores confidence in Regeneron's growth potential among investment experts.
GuruFocus Insight: Understanding GF Value
GuruFocus estimates the GF Value of Regeneron Pharmaceuticals Inc (REGN, Financial) to be $906.31 in one year, suggesting a 65.24% upside from the current price of $548.48. The GF Value calculates what the stock should ideally be traded at, based on historical trading multiples and the company's growth trajectory alongside future business performance estimates. For more detailed insights, explore the Regeneron Pharmaceuticals Inc (REGN) Summary page.
